Daré Bioscience, Inc.
DARE
$1.75
$0.031.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -57.10K | -17.70K | 25.90K | 9.80K | 1.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.10K | -17.70K | 25.90K | 9.80K | 1.88M |
| Cost of Revenue | 16.52M | 16.52M | 16.52M | 17.58M | 24.92M |
| Gross Profit | -16.58M | -16.54M | -16.49M | -17.57M | -23.04M |
| SG&A Expenses | 9.18M | 8.72M | 8.79M | 9.16M | 10.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.41M | 18.46M | 22.04M | 23.46M | 24.92M |
| Operating Income | -17.47M | -18.48M | -22.01M | -23.45M | -23.03M |
| Income Before Tax | -17.46M | -18.60M | -1.68M | -4.05M | -3.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.46 | -18.60 | -1.68 | -4.05 | -3.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.46M | -18.60M | -1.68M | -4.05M | -3.60M |
| EBIT | -17.47M | -18.48M | -22.01M | -23.45M | -23.03M |
| EBITDA | -16.36M | -17.84M | -21.82M | -23.41M | -22.99M |
| EPS Basic | -1.92 | -2.19 | -0.20 | -0.51 | -0.52 |
| Normalized Basic EPS | -1.25 | -1.42 | -0.17 | -0.37 | -0.31 |
| EPS Diluted | -1.92 | -2.19 | -0.22 | -0.53 | -0.53 |
| Normalized Diluted EPS | -1.25 | -1.42 | -0.18 | -0.37 | -0.31 |
| Average Basic Shares Outstanding | 38.40M | 34.18M | 33.72M | 33.34M | 32.62M |
| Average Diluted Shares Outstanding | 38.40M | 34.18M | 33.79M | 33.41M | 32.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |